# Palladyne AI Corp.: financial statements, quarterly

PDYN · Nasdaq · CIK 1826681 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pdyn.md) · [Financials](/companies/pdyn/financials.md) · [Filings](/companies/pdyn/filings.md) · [Insiders](/companies/pdyn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pdyn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.8](/filings/0000950170-24-126347.md) | [0.7 d](/filings/0000950170-25-024148.md) | [3.4](/filings/0000950170-25-065781.md) | [2.7](/filings/0000950170-25-104024.md) | [0.9](/filings/0001193125-25-275896.md) | [0.8 d](/filings/0001193125-26-092443.md) | [1.7](/filings/0001193125-26-205042.md) | [1.0](/filings/0001193125-26-336656.md) | [0.9](/filings/0001193125-25-275896.md) | [1.7 d](/filings/0001193125-26-092443.md) | [3.5](/filings/0001193125-26-205042.md) | [5.8](/filings/0001193125-26-336656.md) |
| Cost of revenue | $m | [1.2](/filings/0000950170-24-126347.md) | [1.1 d](/filings/0000950170-25-024148.md) | [1.9](/filings/0000950170-25-065781.md) | [0.6](/filings/0000950170-25-104024.md) | [0.5](/filings/0001193125-25-275896.md) | [0.6 d](/filings/0001193125-26-092443.md) | [0.4](/filings/0001193125-26-205042.md) | [0.5](/filings/0001193125-26-336656.md) | [0.5](/filings/0001193125-25-275896.md) | [1.4 d](/filings/0001193125-26-092443.md) | [2.5](/filings/0001193125-26-205042.md) | [4.1](/filings/0001193125-26-336656.md) |
| Research and development | $m | [10.0](/filings/0000950170-24-126347.md) | [7.9 d](/filings/0000950170-25-024148.md) | [2.9](/filings/0000950170-25-065781.md) | [2.3](/filings/0000950170-25-104024.md) | [2.6](/filings/0001193125-25-275896.md) | [2.6 d](/filings/0001193125-26-092443.md) | [2.9](/filings/0001193125-26-205042.md) | [3.1](/filings/0001193125-26-336656.md) | [3.1](/filings/0001193125-25-275896.md) | [3.8 d](/filings/0001193125-26-092443.md) | [3.9](/filings/0001193125-26-205042.md) | [4.3](/filings/0001193125-26-336656.md) |
| Operating income | $m | [(30.8)](/filings/0000950170-24-126347.md) | [(37.1) d](/filings/0000950170-25-024148.md) | [(7.4)](/filings/0000950170-25-065781.md) | [(5.8)](/filings/0000950170-25-104024.md) | [(7.3)](/filings/0001193125-25-275896.md) | [(6.5) d](/filings/0001193125-26-092443.md) | [(6.9)](/filings/0001193125-26-205042.md) | [(8.1)](/filings/0001193125-26-336656.md) | [(8.1)](/filings/0001193125-25-275896.md) | [(9.3) d](/filings/0001193125-26-092443.md) | [(11.9)](/filings/0001193125-26-205042.md) | [(13.4)](/filings/0001193125-26-336656.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-126347.md) | [0.0 d](/filings/0000950170-25-024148.md) | [0.0](/filings/0000950170-25-065781.md) | [0.0](/filings/0000950170-25-104024.md) | [0.0](/filings/0001193125-25-275896.md) | [0.0 d](/filings/0001193125-26-092443.md) | [0.0](/filings/0001193125-26-205042.md) | [0.0](/filings/0001193125-26-336656.md) | [0.0](/filings/0001193125-25-275896.md) | [(2.5) d](/filings/0001193125-26-092443.md) | [0.0](/filings/0001193125-26-205042.md) | [0.0](/filings/0001193125-26-336656.md) |
| Net income | $m | [(29.0)](/filings/0000950170-24-126347.md) | [(36.5) d](/filings/0000950170-25-024148.md) | [(7.2)](/filings/0000950170-25-065781.md) | [(5.3)](/filings/0000950170-25-104024.md) | [(7.1)](/filings/0001193125-25-275896.md) | [(53.0) d](/filings/0001193125-26-092443.md) | [22.8](/filings/0001193125-26-205042.md) | [(7.5)](/filings/0001193125-26-336656.md) | [(3.7)](/filings/0001193125-25-275896.md) | [(1.5) d](/filings/0001193125-26-092443.md) | [(12.6)](/filings/0001193125-26-205042.md) | [(12.3)](/filings/0001193125-26-336656.md) |
| Diluted EPS | $ per share | [(1.13)](/filings/0000950170-24-126347.md) | not reported | [(0.28)](/filings/0000950170-25-065781.md) | [(0.20)](/filings/0000950170-25-104024.md) | [(0.27)](/filings/0001193125-25-275896.md) | not reported | [0.55](/filings/0001193125-26-205042.md) | [(0.20)](/filings/0001193125-26-336656.md) | [(0.09)](/filings/0001193125-25-275896.md) | not reported | [(0.28)](/filings/0001193125-26-205042.md) | [(0.27)](/filings/0001193125-26-336656.md) |
| Basic EPS | $ per share | [(1.13)](/filings/0000950170-24-126347.md) | not reported | [(0.28)](/filings/0000950170-25-065781.md) | [(0.20)](/filings/0000950170-25-104024.md) | [(0.27)](/filings/0001193125-25-275896.md) | not reported | [0.64](/filings/0001193125-26-205042.md) | [(0.20)](/filings/0001193125-26-336656.md) | [(0.09)](/filings/0001193125-25-275896.md) | not reported | [(0.28)](/filings/0001193125-26-205042.md) | [(0.27)](/filings/0001193125-26-336656.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [35.3](/filings/0000950170-23-063750.md) | [23.1](/filings/0000950170-25-024148.md) | [31.8](/filings/0000950170-24-055837.md) | [25.8](/filings/0000950170-24-092881.md) | [21.3](/filings/0000950170-24-126347.md) | [31.2](/filings/0001193125-26-092443.md) | [10.1](/filings/0000950170-25-065781.md) | [20.1](/filings/0000950170-25-104024.md) | [27.4](/filings/0001193125-25-275896.md) | [18.2](/filings/0001193125-26-336656.md) | [17.9](/filings/0001193125-26-205042.md) | [33.8](/filings/0001193125-26-336656.md) |
| Current assets | $m | [61.4](/filings/0000950170-23-063750.md) | [45.1](/filings/0000950170-25-024148.md) | [35.5](/filings/0000950170-24-055837.md) | [30.5](/filings/0000950170-24-092881.md) | [24.7](/filings/0000950170-24-126347.md) | [42.7](/filings/0001193125-26-092443.md) | [50.3](/filings/0000950170-25-065781.md) | [65.8](/filings/0000950170-25-104024.md) | [60.5](/filings/0001193125-25-275896.md) | [52.6](/filings/0001193125-26-336656.md) | [50.3](/filings/0001193125-26-205042.md) | [52.0](/filings/0001193125-26-336656.md) |
| Total assets | $m | [95.6](/filings/0000950170-23-063750.md) | [60.4](/filings/0000950170-25-024148.md) | [50.4](/filings/0000950170-24-055837.md) | [45.1](/filings/0000950170-24-092881.md) | [38.7](/filings/0000950170-24-126347.md) | [56.3](/filings/0001193125-26-092443.md) | [63.3](/filings/0000950170-25-065781.md) | [78.3](/filings/0000950170-25-104024.md) | [72.9](/filings/0001193125-25-275896.md) | [95.7](/filings/0001193125-26-336656.md) | [92.6](/filings/0001193125-26-205042.md) | [94.4](/filings/0001193125-26-336656.md) |
| Current liabilities | $m | [7.9](/filings/0000950170-23-063750.md) | [8.5](/filings/0000950170-25-024148.md) | [5.2](/filings/0000950170-24-055837.md) | [4.7](/filings/0000950170-24-092881.md) | [4.9](/filings/0000950170-24-126347.md) | [4.4](/filings/0001193125-26-092443.md) | [3.1](/filings/0000950170-25-065781.md) | [3.8](/filings/0000950170-25-104024.md) | [4.5](/filings/0001193125-25-275896.md) | [5.7](/filings/0001193125-26-336656.md) | [6.4](/filings/0001193125-26-205042.md) | [8.3](/filings/0001193125-26-336656.md) |
| Total liabilities | $m | [19.4](/filings/0000950170-23-063750.md) | [19.5](/filings/0000950170-25-024148.md) | [16.2](/filings/0000950170-24-055837.md) | [15.3](/filings/0000950170-24-092881.md) | [15.3](/filings/0000950170-24-126347.md) | [65.8](/filings/0001193125-26-092443.md) | [35.0](/filings/0000950170-25-065781.md) | [24.5](/filings/0000950170-25-104024.md) | [21.1](/filings/0001193125-25-275896.md) | [21.0](/filings/0001193125-26-336656.md) | [22.6](/filings/0001193125-26-205042.md) | [23.6](/filings/0001193125-26-336656.md) |
| Shareholders' equity | $m | [76.2](/filings/0000950170-24-126347.md) | [40.9](/filings/0001193125-26-092443.md) | [34.2](/filings/0001193125-25-275896.md) | [29.8](/filings/0001193125-25-275896.md) | [23.4](/filings/0001193125-25-275896.md) | [(9.5)](/filings/0001193125-26-336656.md) | [28.3](/filings/0001193125-26-336656.md) | [53.8](/filings/0001193125-26-336656.md) | [51.8](/filings/0001193125-25-275896.md) | [74.7](/filings/0001193125-26-336656.md) | [69.9](/filings/0001193125-26-336656.md) | [70.8](/filings/0001193125-26-336656.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(20.1) d](/filings/0000950170-24-126347.md) | [(16.5) d](/filings/0000950170-25-024148.md) | [(7.2)](/filings/0000950170-25-065781.md) | [(5.8) d](/filings/0000950170-25-104024.md) | [(4.5) d](/filings/0001193125-25-275896.md) | [(5.1) d](/filings/0001193125-26-092443.md) | [(7.5)](/filings/0001193125-26-205042.md) | [(5.3) d](/filings/0001193125-26-336656.md) | [(6.3) d](/filings/0001193125-25-275896.md) | [(8.5) d](/filings/0001193125-26-092443.md) | [(10.2)](/filings/0001193125-26-205042.md) | [(10.2) d](/filings/0001193125-26-336656.md) |
| Capital expenditure | $m | [0.4 d](/filings/0000950170-24-126347.md) | [(0.3) d](/filings/0000950170-25-024148.md) | [0.1](/filings/0000950170-25-065781.md) | [0.1 d](/filings/0000950170-25-104024.md) | [0.0 d](/filings/0001193125-25-275896.md) | [0.0 d](/filings/0001193125-26-092443.md) | [0.1](/filings/0001193125-26-205042.md) | [0.0 d](/filings/0001193125-26-336656.md) | [0.4 d](/filings/0001193125-25-275896.md) | [0.2 d](/filings/0001193125-26-092443.md) | [0.0](/filings/0001193125-26-205042.md) | [0.9 d](/filings/0001193125-26-336656.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [25.2](/filings/0000950170-23-063750.md) | [25.5](/filings/0000950170-24-055837.md) | [25.5](/filings/0000950170-24-092881.md) | [25.7](/filings/0000950170-24-126347.md) | [25.9](/filings/0000950170-25-065781.md) | [26.6](/filings/0000950170-25-104024.md) | [26.2](/filings/0001193125-25-275896.md) | [41.1](/filings/0001193125-26-205042.md) | [37.7](/filings/0001193125-26-336656.md) | [40.5](/filings/0001193125-25-275896.md) | [45.1](/filings/0001193125-26-205042.md) | [46.0](/filings/0001193125-26-336656.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 49,338,510 at 2026-07-29, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336656.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.